Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $141.90 million
- Book Value:
- Revenue TTM:
- $34.69 million
- Operating Margin TTM:
- Gross Profit TTM:
- $20.73 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cytosorbents Crp had its IPO on 2013-11-07 under the ticker symbol CTSO.
The company operates in the Healthcare sector and Medical Devices industry. Cytosorbents Crp has a staff strength of 198 employees.
Shares of Cytosorbents Crp opened at $3.23 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $3.08 - $3.25, and closed at $3.13.
This is a -3.69% slip from the previous day's closing price.
A total volume of 47,300 shares were traded at the close of the day’s session.
In the last one week, shares of Cytosorbents Crp have slipped by -12.57%.
Cytosorbents Crp's Key Ratios
Cytosorbents Crp has a market cap of $141.90 million, indicating a price to book ratio of 1.3043 and a price to sales ratio of 1.4029.
In the last 12-months Cytosorbents Crp’s revenue was $34.69 million with a gross profit of $20.73 million and an EBITDA of $-30639258. The EBITDA ratio measures Cytosorbents Crp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cytosorbents Crp’s operating margin was -90.87% while its return on assets stood at -25.8% with a return of equity of -67%.
In Q4, Cytosorbents Crp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 12.9%.
Cytosorbents Crp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 106.383 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytosorbents Crp’s profitability.
Cytosorbents Crp stock is trading at a EV to sales ratio of 1.3333 and a EV to EBITDA ratio of -1.2593. Its price to sales ratio in the trailing 12-months stood at 1.4029.
Cytosorbents Crp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $63.23 million
- Total Liabilities
- $9.71 million
- Operating Cash Flow
- Capital Expenditure
- $6.61 million
- Dividend Payout Ratio
Cytosorbents Crp ended 2023 with $63.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $63.23 million while shareholder equity stood at $35.37 million.
Cytosorbents Crp ended 2023 with $0 in deferred long-term liabilities, $9.71 million in other current liabilities, 43635.00 in common stock, $-253997878.00 in retained earnings and $0 in goodwill. Its cash balance stood at $22.14 million and cash and short-term investments were $22.14 million. The company’s total short-term debt was $108,939 while long-term debt stood at $0.
Cytosorbents Crp’s total current assets stands at $33.76 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.66 million compared to accounts payable of $1.66 million and inventory worth $3.46 million.
In 2023, Cytosorbents Crp's operating cash flow was $-206080.00 while its capital expenditure stood at $6.61 million.
Comparatively, Cytosorbents Crp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cytosorbents Crp stock is currently trading at $3.13 per share. It touched a 52-week high of $4.59 and a 52-week low of $4.59. Analysts tracking the stock have a 12-month average target price of $8.4.
Its 50-day moving average was $2.98 and 200-day moving average was $2.08 The short ratio stood at 4.86 indicating a short percent outstanding of 0%.
Around 988.5% of the company’s stock are held by insiders while 3764% are held by institutions.
Frequently Asked Questions About Cytosorbents Crp
Similar Industry Stocks (Medical Devices)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.